Novel method could optimise beta-blocker synthesis
The proposed synthesis system offers potential for scalable production of β-blockers, new research suggests.
List view / Grid view
The proposed synthesis system offers potential for scalable production of β-blockers, new research suggests.
Here, Vladimir Murovec, Counsel, Osborne Clarke, discusses the European Medicines Agency (EMA)’s latest draft reflection paper and its scientific rationale, regulatory implications and potential impact on biosimilar drug development and manufacturing in the EU.
The investment will support the company’s long-term vision for its future manufacturing capacity and medicine pipeline.
The UK medicine agency's most recent recalls of this class have been due to packaging and potential contamination issues.
The new manufacturing site features automation capabilities to ensure efficient production and supports advancement of potential next-generation microbial therapies.
The UK Government’s £86 billion announcement will help strengthen innovation and economic growth in key sectors including life sciences.
Stefan Braam, Chief Technology Officer, Cellistic, explores the manufacturing and regulatory challenges of scalable, off-the-shelf iPSC-NK cell therapies.
MHRA’s publication is intended to support European developers of phage-based medicinal products to effectively navigate related regulations.
This exclusive report addresses the key obstacles and innovations shaping pharmaceutical environmental monitoring, from QC and contamination control, to the impact of advanced technologies and regulatory changes. Discover practical solutions you can implement to drive progress for your organisation.
The agreement involves an immunotherapy candidate with potential to innovate treatment of multiple tumour types, stated BMS.
Overcome matrix interferences in RNA–LNP endotoxin testing with LAL-based methods & recombinant factor C assays. Learn more in this whitepaper.
The innovative device could improve CAR T cell cancer immunotherapy and facilitate its use as a first-line therapy, research suggests.
20 May 2025 | By US Pharmacopeia
Join this webinar to learn about the essential role of Reference Standards in mitigating risks to pharmaceutical quality.
This exclusive report addresses the key challenges and breakthroughs shaping the future of cell and gene therapy, from QC and analytical development to advanced manufacturing strategies. Discover practical solutions you can implement to drive progress for your organisation.
12 May 2025 | By Mettler Toledo
This virtual panel explores impurity control in pharmaceutical waters, the differences between microbial and organic contaminants, and best practices for measurement and treatment.